B+
Bull case
25%
Probability
Target price
$0.55
-91.3% vs current
SILO
SiloFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-15
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$0.42
-93.4% vs current
B-
Bear case
30%
Probability
Target price
$0.24
-96.2% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
This remains a cautious monitoring memo. The scheduled May 7, 2026 post-earnings follow-up could not be anchored to a company earnings release, 10-Q, or earnings 8-K in recent SEC filings checked through May 9, 2026, so earnings surprise, guidance revision, and analyst target-change signals are unavailable rather than positive. News flow in the packet is thin and generic, and the stock's move from the May 7 anchor price of $0.42 to about $0.405 on May 9 appears muted and not clearly earnings-linked. With low coverage, limited trusted secondary reaction, and a thesis still dominated by one clinical/regulatory milestone, confidence should stay capped.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystNon-core QwikAgents acquisition adds strategy and dilution scrutinyHigh impact
The April 2, 2026 8-K disclosed the purchase of QwikAgents software and related domains for 2.1 million common shares, a material issuance that may complicate the biotech thesis and investor positioning [#8-K-2026-04-02].
2026-12-31eventSPC-15 IND path remains the main value inflectionHigh impact
The 2026 10-K says SPC-15 had a pre-IND meeting with FDA in September 2024, GLP pharmacokinetic/pharmacodynamic and toxicology work is underway, and management is aiming for an IND submission in 2026 [#10-K-2026-03-27].
2027-03-27catalystNear-term liquidity pressure is lower than in prior going-concern periodsHigh impact
The 2026 10-K reported working capital of $6.7 million at December 31, 2025 and stated cash was sufficient to meet obligations for at least twelve months from the filing date, which reduces immediate balance-sheet stress even if it does not remove future financing risk [#10-K-2026-03-27].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology